Abstract
Anal cancer is rare, but certain populations are at increased risk for this type of tumor, being the third most commonly reported malignancy among HIV positive individuals. Unlike the majority of malignancies occurring in this population, the anal cancer can be prevented. The success of cervical cancer screening in reducing its incidence has led to point this strategy as a criterion for performing the anal cancer screening. However, this protocol has been used mostly and widely for conducting the scientific researches, with a few exceptions only. This study reviews the topics on anal cancer, its risk factors and its diagnosis, in order to alert the scientific community and the health professionals about the importance of anal cancer screening and its monitoring in HIV infected patients.
References
1. Bean SM, Chhieng DC. Anal-rectal cytology: a review. Diagn Cytopathol. 2010;38(7):538-46. [DOI: http://dx.doi.org/10.1002/dc.21242].
2. Deeken JF, Tjen-A-Looi A, Rudek MA, Okuliar C, Young M, Little RF, et al. The rising challenge of non–AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012;55(9):1228-35. [DOI: http://dx.doi.org/10.1093/cid/cis613].
3. Grulich AE. Epidemiology of Non-AIDS-Defining Malignancies. In: Hope TJ, Stevenson M, Richman D, editors. Encyclopedia of AIDS. New York: Springer; 2013. p. 1-8.
4. Sahasrabuddhe VV, Castle PE, Follansbee S, Borgonovo S, Tokugawa D, Schwartz LM, et al. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J Infect Dis. 2013;207(3):392-401. [DOI: http:// dx.doi.org/10.1093/infdis/jis694].
5. Smyczek P, Singh AE, Romanowski B. Anal intraepithelial neoplasia: review and recommendations for screening and management. Int J STD AIDS. 2013;24(11):843-51. [ DOI: http:// dx.doi.org/10.1177/0956462413481527].
6. Pandey P. Anal anatomy and normal histology. Sex Health. 2012;9(6):513-6. [DOI: http://dx.doi. org/10.1071/SH12034].
7. Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330-9. [DOI: http:// dx.doi.org/10.1016/j.ejso.2014.07.030].
8. Fenger C, Frisch M, Marti MC, Parc R. Tumours of the anal canal. In: Hamilton SR, Aaltonen LA, editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press; 2000.
9. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000;342(11):792-800. [DOI: http://dx.doi.org/10.1056/ NEJM200003163421107].
10. Licitra L, Spinazzé S, Doci R, Evans TJ, Tanum G, Ducreux M. Cancer of the anal region. Crit Rev Oncol Hemat. 2002;43(1):77-92. [DOI: http://dx.doi.org/10.1016/S1040-8428(01)00193-7].
11. Shridhar R, Shibata D, Chan E, Thomas CR. Anal cancer: Current standards in care and recent changes in practice. CA Cancer J Clin. 2015;65(2):139-62. [DOI: http://dx.doi.org/10.3322/caac.21259].
12. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer. 2004;101(2):281-8. [DOI: http://dx.doi.org/10.1002/ cncr.20364].
13. Instituto Nacional de Câncer, Ministério da Saúde. Estimativa 2016: Incidência de câncer no Brasil. Rio de Janeiro: INCA; 2015. [acesso 2016 Jan 16]. Disponível em: [http://www.inca.gov.br/ estimativa/2016/estimativa-2016-v11.pdf].
14. Larangeira LLS, Andrade SKV. Incidência do carcinoma de canal anal na regional de saúde de Londrina (PR). Rev bras Coloproct. 2004;24(3):240-6.
15. Brickman C, Palefsky JM. Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. Curr HIV/AIDS Rep. 2015;12(1):6-15. [DOI: http:// dx.doi.org/10.1007/s11904-014-0254-4].
16. Benevolo M, Dona’ MG, Ravenda PS, Chiocca S. Anal human papillomavirus infection: prevalence, diagnosis and treatment of related lesions. Expert Rev Anti-infect Ther. 2016;14(5):465-77. [DOI: http://dx.doi.org/10.1586/14787210.2016.1174065].
17. Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist. 2007;12(5):524-34. [DOI: http://dx.doi. org/10.1634/theoncologist.12-5-524].
18. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270-80. [DOI: http://dx.doi. org/10.1002/cncr.20365].
19. Melo VH, Guimaraes MDC, Rocha GM, Araujo ACL, Carmo RA, Grinsztejn B, et al. Prevalence and risk factors associated with anal intraepithelial neoplasia among HIVpositive men in Brazil. J Low Genit Tract Dis. 2014;18(2):128-35. [DOI: http://dx.doi.org/10.1097/ LGT.0b013e31829ee855].
20. Darragh TM, Winkler B. Anal cancer and cervical cancer screening: key differences. Cancer Cytopathol. 2011;119(1):5-19. [DOI: http://dx.doi.org/10.1002/ cncy.20126].
21. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550-60. [DOI: http:// dx.doi.org/10.1038/nrc2886].
22. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res. 2006;19(1):99-105. [DOI: http:// dx.doi.org/10.1177/154407370601900120].
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2016 Instituto Adolfo Lutz Journal